Skip to Content

Cilastatin / imipenem Pregnancy and Breastfeeding Warnings

Cilastatin / imipenem is also known as: Primaxin IM, Primaxin IV

Medically reviewed on March 12, 2018.

Cilastatin / imipenem Pregnancy Warnings

Imipenem-cilastatin has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity. However, some species experienced reduced maternal tolerance of the drug during pregnancy. There are no controlled data in human pregnancies. Imipenem-cilastatin should only be given during pregnancy when benefit outweighs risk.

See references

Cilastatin / imipenem Breastfeeding Warnings

Imipenem-cilastatin is excreted into human milk in small amounts. The manufacturer recommends caution if imipenem-cilastatin is administered to a nursing woman.

See references

References for pregnancy information

  1. "Product Information. Primaxin (imipenem)." Merck & Co, Inc, West Point, PA.
  2. Heikkila A, Erkkola R "Review of beta-lactam antibiotics in pregnancy - the need for adjustment of dosage schedules." Clin Pharmacokinet 27 (1994): 49-62

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Primaxin (imipenem)." Merck & Co, Inc, West Point, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide